Search for Clinical Trial Results

Sponsored By

Ewing Sarcoma - 29 Studies Found

Status Study
Withdrawn Study Name: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma
Condition: Ewing Sarcoma
Date: 2013-10-21
Interventions:
  • Biological: allogeneic stem cell transplantation
Recruiting Study Name: Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Condition: Ewing's Sarcoma
Date: 2013-02-21
Interventions:
  • Drug: Standard treatment (as per protocol ISG SSG III)

Recruiting Study Name: A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma
Condition: Ewing's Sarcoma
Date: 2015-07-28
Interventions:
  • Biological: Vigil Vigil 1.0 x

Active, not recruiting Study Name: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Condition: Ewing's Sarcoma
Date: 2011-06-30
Interventions:
  • Drug: Chemotherapy

Recruiting Study Name: Study in Localized and Disseminated Ewing Sarcoma
Condition: Ewing's Sarcoma
Date: 2009-09-30
Interventions:
  • Drug: Zoledronic acid

Terminated Study Name: Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
Condition: Ewing's Sarcoma
Date: 2007-12-05
Interventions: Drug: VCR, CTX, ADM; IFO, VP-16 VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2
Completed Study Name: Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma
Condition: Non-Metastatic Ewings Sarcoma
Date: 2006-06-19
Completed Study Name: Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
Condition: Ewing's Sarcoma
Date: 2007-06-26
Interventions:
  • Drug: Temozolomide Cycle 2, Do
Terminated Study Name: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Condition: Ewing's Sarcoma
Date: 2002-05-29
Interventions:
  • Drug: Vincristine 2.0 mg/m^2 (
Available Study Name: Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Date: 2017-01-20
Interventions: Drug: Ganitumab The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clin
Next >>>